Stay updated with breaking news from வலேரியா மீனவர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(0) Modra Pharmaceuticals ( Modra ) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board. The new members bring more than 50 years of combined experience in the pharmaceutical and biotechnology industry, and will provide guidance critical for the acceleration of Modra s growth and business development efforts, as well as the company s plans for the advancement of lead clinical candidate, ModraDoc006/r, a boosted oral formulation of docetaxel. Modra recently presented preliminary data from its Phase IIb trial of ModraDoc006/r, which showed a positive safety and tolerability profile in metastatic castrate resistant prostate cancer. ....
Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 with product launch anticipated in 2021 1 Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021 PXL065 Phase 2 study ongoing with completion of recruitment expected in mid-2021 and topline data readout in mid-2022 Imeglimin and PXL065 preclinical and clinical data published in peer reviewed journals; PXL770 data accepted for oral and poster presentations at an upcoming scientific conference ....
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Expansion study planned upon definition of recommended dose to gather additional data Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company ....
(0) First pivotal study to compare Peptide Receptor Radionuclide Therapy (PRRT) in patients with Grade 1 and 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with approved standard of care ITM AG today announced the presentation of a trial-in-progress poster highlighting its ongoing Phase III trial COMPETE with n.c.a. 177Lu-Edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The poster will be presented in video format as part of the Phase III trials in progress poster session by Mona M. Wahba, MD, Deputy Chief Medical Officer at ITM. It will be available following the e-poster website launch on April 10, 2021, at 8:30 am ET 2:30 pm CET and remain available for viewing through June 21, 2021. ....